Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04669808 · ClinicalTrials.gov registry record · Phase 2
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
A Phase 2 study of Basal Cell Carcinoma, sponsored by Sirnaomics.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT04669808 is a Phase 2 study of Basal Cell Carcinoma that has completed, run by Sirnaomics. The registered enrollment target is 32 participants, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04669808, a Phase 2 study of Basal Cell Carcinoma, has completed, sponsored by Sirnaomics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma. * Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.
Conditions Studied
Interventions
- DRUG STP705
Study Locations (1)
Florida
- Center for Clinical and Cosmetic Research - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2023-02-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04669808
The ClinicalTrials.gov registry entry for NCT04669808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 24 other Basal Cell Carcinoma trials with a reported enrollment target (69% lower). The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Basal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which STP705 is the first listed.
NCT04669808 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04669808 about?
NCT04669808 is a clinical study titled "Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma". This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: * To determine the safe and effective recommended dose of STP705 for the ...
What is the current status of trial NCT04669808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2020-12-28. Estimated completion is 2023-02-09.
What conditions does trial NCT04669808 study?
This clinical trial studies the following conditions: Basal Cell Carcinoma.
What interventions are being tested in trial NCT04669808?
The interventions under investigation include: STP705 (DRUG).
Who is sponsoring clinical trial NCT04669808?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04669808 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
RECRUITING · Phase 2
-
Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
RECRUITING · Phase 2
-
Alteration of the Immune Microenvironment in Basal Cell Carcinoma Following Photodynamic Therapy
RECRUITING · Phase 2
-
To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma
RECRUITING · Phase 2
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.